Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biological & Pharmaceutical Bulletin|February 3, 2007
Rakicidin A: a hypoxia-selective cytotoxinYohko Yamazaki, Setsuko Kunimoto, Daishiro Ikeda
Biochemical and Biophysical Research Communications|January 27, 2009
Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cellsIsao Momose, Setsuko Kunimoto, Michiyo Osono, et al.
Biological & Pharmaceutical Bulletin|October 24, 2002
Induction of p16/INK4a gene expression and cellular senescence by toyocamycinYosuke Kurihara, Kiyoshi Egawa, Setsuko Kunimoto, et al.
The Journal of Antibiotics|April 9, 2005
Absolute configuration of kigamicins A, C and DTetsuya Someno, Setsuko Kunimoto, Hikaru Nakamura, et al.
Biological & Pharmaceutical Bulletin|April 4, 2003
HIF-1-dependent VEGF reporter gene assay by a stable transformant of CHO cellsYohko Yamazaki, Kiyoshi Egawa, Kiyoshi Nose, et al.
Cancer Science|June 9, 2004
Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvationJie Lu, Setsuko Kunimoto, Yohko Yamazaki, et al.
The Journal of Antibiotics|March 16, 2004
Kigamicins, novel antitumor antibiotics. II. Structure determinationSetsuko Kunimoto, Tetsuya Someno, Yohko Yamazaki, et al.
Biological & Pharmaceutical Bulletin|October 4, 2006
Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activationYohko Yamazaki, Yuki Hasebe, Kiyoshi Egawa, et al.
Biological & Pharmaceutical Bulletin|October 2, 2003
Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoidsYuki Hasebe, Kiyoshi Egawa, Yoko Yamazaki, et al.
The Journal of Antibiotics|July 13, 2006
Antitumor effect of kigamicin D on mouse tumor modelsToru Masuda, Shunichi Ohba, Manabu Kawada, et al.
Pageof 2